Ignite Creation Date:
2025-12-24 @ 4:55 PM
Ignite Modification Date:
2026-01-02 @ 9:56 AM
Study NCT ID:
NCT01229150
Status:
COMPLETED
Last Update Posted:
2017-05-23
First Post:
2010-10-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non Small Cell Lung Carcinoma | View |